DFS
Fig. 2 · Panel DFS_Kaplan-Meier_curve
Panel DFS_Kaplan-Meier_curve 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Ning Li, Wei Ou, Chao Cheng, Jian You, Lin Yang, Feng-Xia Chen, Yi Liang, Zhixiong Yang, Bao-Xiao Wang, Zeng-Hao Chang, Yao-Bin Lin, Weixiong Yang, Feng Xu, Guanggui Ding, Xian-Shan Chen, Ronggui Hu, Shujun Li, Hao Jiang, Xin-Xin Hu, Hao Long, Si-Yu Wang
Signal Transduct Target Ther 10(1) 273
The efficacy, safety and ideal treatment duration of an adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for patients with resected EGFR-mutated non-small-cell lung cancer (NSCLC) were not known until 2014, when this study was initiated. In this phase 3 ICTAN trial (GASTO1002, NCT01996098), patients with completely resected, EGFR-mutated, stage II-IIIA NSCLC after adjuvant chemotherapy were assigned in a 1:1:1 ratio to receive icotinib (125 mg, three times daily) for 12 months, to receive icotinib for 6 months, or to undergo observation. The primary endpoint was disease-free survival (DFS). This trial was terminated early. A total of 251 patients were randomized. Adjuvant icotinib for 12 months significantly improved DFS (hazard ratio [HR]: 0.40, 95% confidence interval [CI], 0.27-0.61; P < 0.001) and overall survival (OS; HR: 0.55, 95% CI, 0.32-0.96; P = 0.032) compared with observation. Adjuvant icotinib of 6 months also significantly improved DFS (HR: 0.41, 95% CI, 0.27-0.62; P < 0.001) and OS (HR: 0.56, 95% CI, 0.32-0.98; P = 0.038) compared with observation. Adjuvant icotinib for 12 months did not improve DFS (HR: 0.97; P = 0.89) or OS (HR: 1.00; P = 0.99) compared with 6 months of this drug. Rates of adverse events of grade 3 or higher were 8.3%, 6.0% and 2.4% for the 12-month icotinib, 6-month icotinib, and observation groups, respectively. Adjuvant icotinib for 12 months or 6 months following adjuvant chemotherapy improved DFS and OS compared with observation in patients with resected EGFR-mutated stage II-IIIA NSCLC with a manageable safety profile, supporting it as a potential treatment option.
2 个 Figure · 2 个 KM 面板
Fig. 2 Kaplan-Meier estimates of DFS by the investigator in the ITT population. DFS disease-free survival, HR hazard ratio, CI confidence interval, ITT intention-to-treat
Fig. 2 · Panel DFS_Kaplan-Meier_curve
Panel DFS_Kaplan-Meier_curve 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 Kaplan-Meier estimates of OS in the ITT population. OS, overall survival; HR, hazard ratio; CI, confidence interval; ITT, intention-to-treat
Fig. 4 · Panel OS
Panel OS 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。